Increased pSmad2 expression and cytoplasmic predominant presence of TGF-βRII in breast cancer tissue are associated with poor prognosis: results from the Shanghai Breast Cancer Study

[1]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[2]  X. Shu,et al.  Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study , 2011, BMC Cancer.

[3]  R. Shepherd,et al.  Flow-dependent Smad2 phosphorylation and TGIF nuclear localization in human aortic endothelial cells. , 2011, American journal of physiology. Heart and circulatory physiology.

[4]  Kohei Miyazono,et al.  TGFβ signalling: a complex web in cancer progression , 2010, Nature Reviews Cancer.

[5]  Gretchen L. Gierach,et al.  Expression of TGF-β signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics , 2010, Breast Cancer Research and Treatment.

[6]  C. Paiva,et al.  Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[8]  X. Shu,et al.  Circulating transforming growth factor-β-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study , 2008, Breast Cancer Research and Treatment.

[9]  Xu Zhang,et al.  A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model , 2007, Comput. Methods Programs Biomed..

[10]  J. Massagué,et al.  The logic of TGFβ signaling , 2006 .

[11]  R. Derynck,et al.  SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS , 2005 .

[12]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.

[13]  P. Fritz,et al.  Prognostic Significance of Transforming Growth Factor β Receptor II in Estrogen Receptor-Negative Breast Cancer Patients , 2004, Clinical Cancer Research.

[14]  C. Hill,et al.  Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. , 2002, Molecular cell.

[15]  L. Wakefield,et al.  Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. , 2002, The American journal of pathology.

[16]  T. Muir,et al.  Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. , 2001, Molecular cell.

[17]  T. Sellers,et al.  Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai breast cancer study , 2000, International journal of cancer.

[18]  Simpson,et al.  Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in‐situ and invasive carcinomas , 2000, Histopathology.

[19]  J. Massagué,et al.  Structural basis of Smad2 recognition by the Smad anchor for receptor activation. , 2000, Science.

[20]  K. Kinzler,et al.  Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. , 1999, Cancer research.

[21]  Takeshi Imamura,et al.  TGF‐β receptor‐mediated signalling through Smad2, Smad3 and Smad4 , 1997 .

[22]  C. Arteaga,et al.  Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells. , 1997, Cancer research.

[23]  M. Ohue,et al.  Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. , 1997, Cancer letters.

[24]  P. Hoodless,et al.  MADR2 Is a Substrate of the TGFβ Receptor and Its Phosphorylation Is Required for Nuclear Accumulation and Signaling , 1996, Cell.

[25]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[26]  K. Lewis,et al.  Molecular characterization of rat transforming growth factor-β type II receptor , 1993 .

[27]  Jeffrey L. Wrana,et al.  TGFβ signals through a heteromeric protein kinase receptor complex , 1992, Cell.

[28]  Sunil R. Lakhani,et al.  WHO classification of tumours of the breast , 2012 .

[29]  S. Chowdhury,et al.  Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy. , 2009, Molecular and cellular pharmacology.

[30]  W. Zheng.  Genetic polymorphisms in the transforming growth factor-beta signaling pathways and breast cancer risk and survival. , 2009, Methods in molecular biology.

[31]  J. Massagué,et al.  The logic of TGFbeta signaling. , 2006, FEBS letters.

[32]  R. Derynck,et al.  Specificity and versatility in tgf-beta signaling through Smads. , 2005, Annual review of cell and developmental biology.

[33]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[34]  J. Massagué,et al.  TGFbeta signaling in growth control, cancer, and heritable disorders. , 2000, Cell.

[35]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[36]  H. Lodish,et al.  Molecular characterization of a type I serine-threonine kinase receptor for TGF-beta and activin in the rat pituitary tumor cell line GH3. , 1995, Experimental cell research.

[37]  K. Lewis,et al.  Molecular characterization of rat transforming growth factor-beta type II receptor. , 1993, Biochemical and biophysical research communications.

[38]  J. Massagué,et al.  TGF beta signals through a heteromeric protein kinase receptor complex. , 1992, Cell.